Company: EVGN
Filing Date: 2025-09-30
Form Type: POS AM
Source: 0001178913-25-003429
Chunk: 5

Company: Evogene Ltd.
Filing Date: 2025-09-30
Form: POS AM
Chunk 5
---
 part of our new strategy, we are building a dedicated business development team in pharma. In addition, we are optimizing our agricultural offering around ChemPass AIthrough the integration of our subsidiary’s, AgPlenus, activity into Evogene, as part of which we have effected a 40% workforce reduction at AgPlenus and 30% workforce reduction at Evogene. That streamlining process is part of our overall cost reduction plan, most of which was completed by the end of the second quarter of 2025, the initial impact of which was partially reflected in our 2025 first-half results, and the full effect of which is expected to be realized in the second half of 2025 and the first quarter of 2026. The expected upcoming activities for our other subsidiaries are as follows:

| • | Lavie Bio: Following the divestiture of the majority of its activities and assets in July 2025, our subsidiary, Lavie Bio, is now focused on maintaining a collaboration with its existing partner. Dividends are expected to be 
 distributed by Lavie Bio to Evogene, its majority shareholder. No new initiatives are planned for Lavie Bio currently.                                                                                                           |

| • | Biomica: Our subsidiary, Biomica, is advancing towards completion of its clinical trial for BMC128 and exploring potential partners to take the lead on its current development programs. No new initiatives are planned for Biomica 
 currently.                                                                                                                                                                                                                           |

| • | Casterra – Our subsidiary, Casterra, has shown strong potential for generating revenue and has been expanding into new markets. We intend to support its continued development. |

For additional information about our business, you should refer to our reports under the Exchange Act, referenced under the heading “Information Incorporated by Reference.” Before making an investment decision, you should read this entire prospectus, and our other filings with the SEC, including those filings incorporated herein and therein by reference, carefully, including the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”. Corporate Information Our registered office and principal place of business is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel, and our telephone number in Israel is +972 (8) 931-1900. Our website address is http://www.evogene.com. We have included our website address in this prospectus solely as an inactive textual reference. Our registered agent in the United States is Puglisi & Associates, whose address